Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis

• Published in: Autoimmunity reviews 2022-10, Vol.21 (10), p.103158, Article 103158
• Main Authors: Domingues, Vinicius, Chock, Eugenia Yupei, Dufrost, Virginie, Risse, Jessie, Seshan, Surya V., Barbhaiya, Medha, Sartelet, Hervé, Erkan, Doruk, Wahl, Denis, Zuily, Stephane
• Format: Article
• Language: English
• Subjects: Antiphospholipid syndrome; Fibrous intimal hyperplasia; Focal cortical atrophy; IgG; Lupus anticoagulant; Lupus nephritis; Thrombotic microangiopathy; Tubular thyroidization
• ISSN: 1568-9972; 1568-9972
• DOI: 10.1016/j.autrev.2022.103158

Microvascular renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their association with aPL is inconsistent among studies. Therefore, our objective was to investigate associations between microvascular renal lesions and aPL among systemic lupus erythematosus (SLE) patients. Studies were selected if they included SLE patients with and without aPL positivity with a description of kidney biopsy identifying acute and/or chronic microvascular renal lesions as well as lupus nephritis. Data sources were Pubmed, Embase, Cochrane Library, hand search, congress abstracts, and reference lists of studies, without language restrictions. Risk estimates were independently extracted by 2 investigators. Pooled effect estimates were obtained by using the Mantel-Haenszel method (random effects). Of 1860 identified records obtained between 1991 and 2021, 35 published studies (10 cohorts, 7 case-control, 18 cross-sectional) met inclusion criteria, including 3035 SLE patients according to American College of Rheumatology criteria and 454 cases of microvascular renal lesions. Frequency of microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 31.3% vs. 10.4%, respectively. The overall pooled odds ratios (OR) for microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 3.03 (95% confidence interval [CI], 2.25–4.09). The risk of microvascular renal lesions was the highest for lupus anticoagulant (OR = 4.84 [95% CI, 2.93 to 8.02]) and IgG anticardiolipin antibodies (OR = 3.12 [95% CI,1.08–9.02]) while the association with anti-β2-glycoprotein I antibodies (OR = 1.88 [95% CI, 0.25–14.14]) did not reach statistical significance. Furthermore, aPL were not associated with any classes of lupus nephritis. In SLE patients, aPL-positivity is associated with a significant 3- to 5-fold increased risk for specific microvascular renal lesions. This risk is mainly driven by lupus anticoagulant and IgG anticardiolipin antibodies. Our results support the inclusion of microvascular renal lesions as new criteria for definite antiphospholipid syndrome. •The risk of acute or chronic microvascular renal lesions in aPL patients is increased by 3 to almost 5 fold.•Lupus anticoagulant and IgG aCL antibodies are associated with the highest risk of microvascular renal lesions.•Main microvascular renal lesions associated with aPL are TMA, focal cortical atrophy, fibrous intimal hyperplasia and tubular thyroidization.•Lupu